atai Life Sciences to Participate in October Investor Events & Host Virtual R&D Day
October 04 2022 - 7:00AM
atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage
biopharmaceutical company aiming to transform the treatment of
mental health disorders, will participate in in the following
investor events & host a virtual R&D Day in October:
- Roth Inaugural Healthcare Opportunities Conference in
New York CityFormat: Company presentationDate and Time:
Thursday, October 6th, 11:45 a.m. ET – 12:15 p.m. ETConference
link: Roth Inaugural Healthcare Opportunities Conference
- Cantor Fitzgerald’s Neurology & Psychiatry
Conference in San FranciscoFormat: Industry panelsDate and
Time: Thursday, October 6th, 2:10 p.m. ET – 3:10 p.m. ET &
Friday, October 7th, 11:00 a.m. – 12:00 p.m. ETConference link:
Cantor Fitzgerald’s Neurology & Psychiatry Conference
- atai Life Sciences Virtual R&D DayFormat:
Company presentation and KOL discussionsDate and Time: Tuesday,
October 25th, 12:00 p.m. ETWebcast link: TBA
Archived webcasts will be accessible in the Events section of
atai’s website where they will be available for up to 90 days.
About atai Life Sciencesatai Life Sciences is a
clinical-stage biopharmaceutical company aiming to transform the
treatment of mental health disorders. Founded in 2018 as a response
to the significant unmet need and lack of innovation in the mental
health treatment landscape, atai is dedicated to acquiring,
incubating, and efficiently developing innovative therapeutics to
treat depression, anxiety, addiction, and other mental health
disorders.
By pooling resources and best practices, atai aims to
responsibly accelerate the development of new medicines across its
companies to achieve clinically meaningful and sustained behavioral
change in mental health patients.
atai's vision is to heal mental health disorders so that
everyone, everywhere can live a more fulfilled life. For more
information, please visit www.atai.life.
Forward-Looking StatementsThese presentations
may contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Any expressed or
implied statements contained in these presentations that are not
statements of historical fact may be deemed to be forward-looking
statements. Forward-looking statements are neither promises nor
guarantees, but involve known and unknown risks and uncertainties
that could cause actual results to differ materially from those
projected, including, without limitation, the important factors
described in the section titled “Risk Factors” in our most recent
Annual Report on Form 10-K filed with the Securities and Exchange
Commission (“SEC”), as updated by our subsequent filings with the
SEC, as such factors may be updated from time to time in atai's
other filings with the SEC. atai disclaims any obligation or
undertaking to update or revise any forward-looking statements
contained in this press release, other than to the extent required
by applicable law.
Contact Information
Investor Contact:Stephen BardinChief Financial OfficerEmail:
IR@atai.life
Media Contact:Allan MalievskySenior Director of External
AffairsEmail: PR@atai.life
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Apr 2023 to Apr 2024